Quarterly report pursuant to Section 13 or 15(d)

Nature of Business and Liquidity (Details)

v3.20.1
Nature of Business and Liquidity (Details)
3 Months Ended
Mar. 31, 2020
candidate
approach
technology
drug
Product Information [Line Items]  
Number of core drug technologies | technology 3
Number of drug candidates | candidate 6
Number of different approaches to treating cancer | approach 3
Number of drugs in clinical trials | drug 2
Licensing Agreements  
Product Information [Line Items]  
Market exclusivity period 7 years
Food and Drug Administration  
Product Information [Line Items]  
Market exclusivity extension period 5 years
European Union  
Product Information [Line Items]  
Market exclusivity extension period 10 years
Animal Life Science  
Product Information [Line Items]  
Ownership interest 10.00%